Human disease
AL amyloidosis
Mondo defines it as: “AL Amyloidosis is a plasma cell disorder characterized by the aggregation and deposition of insoluble amyloid fibrils derived from misfolding of monoclonal immunoglobulin light chains usually produced by a plasma cell tumor. It usually presents as primary systemic amyloidosis (PSA) with multiple organ involvement and less frequently as primary localized amyloidosis (PLA) restricted to a single organ.”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 39 | Amyloidosis, AL | The group's name | 3 | Human disease |
37.5
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
Open Targets links none of these groups' human genes to this disease.
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Tafamidis | None of these genes | Approved |
| Anselamimab | None of these genes | Phase 3 |
| Birtamimab | None of these genes | Phase 3 |
| Bortezomib | None of these genes | Phase 3 |
| Coagulation Factor X Human | None of these genes | Phase 3 |
| Daratumumab | None of these genes | Phase 3 |
| Dexamethasone | None of these genes | Phase 3 |
| Melphalan | None of these genes | Phase 3 |
| Doxycycline Anhydrous | None of these genes | Phase 2/3 |
| Cyclophosphamide Anhydrous | None of these genes | Phase 2 |
| Elotuzumab | None of these genes | Phase 2 |
| Epigalocatechin Gallate | None of these genes | Phase 2 |
| Equecabtagene Autoleucel | None of these genes | Phase 2 |
| Filgrastim | None of these genes | Phase 2 |
| Isatuximab | None of these genes | Phase 2 |
| Lenalidomide | None of these genes | Phase 2 |
| Pomalidomide | None of these genes | Phase 2 |
| Sonrotoclax | None of these genes | Phase 2 |
| Teclistamab | None of these genes | Phase 2 |
| Venetoclax | None of these genes | Phase 2 |
| Elranatamab | None of these genes | Phase 1/2 |
| Fludarabine | None of these genes | Phase 1/2 |
| Ixazomib | None of these genes | Phase 1/2 |
| Ixazomib Citrate | None of these genes | Phase 1/2 |
| Carfilzomib | None of these genes | Phase 1 |
| Selinexor | None of these genes | Early phase 1 |
| Antilymphocyte Immunoglobulin (Horse) | None of these genes | Unknown |
| Tacrolimus Anhydrous | None of these genes | Unknown |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.